ArticleFrontiers in pharmacology2026
Treatment of children with acute upper respiratory tract infection (wind-heat pattern) with Yin Hu Gan Mao San: a prospective real-world cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Yin Hu Gan Mao San (YHGMS) is a traditional Chinese herbal preparation derived from Yin Qiao San, used for topical application to treat wind-heat colds. This study aims to evaluate the clinical efficacy and safety of YHGMS in children with acute upper respiratory tract infection (AURTI) of wind-heat pattern. Methods: This prospective, real-world cohort study enrolled 999 children with AURTI from 23 hospitals from May 2022 to June 2023. Participants were naturally divided into an exposed group (n = 671) that received YHGMS and a non-exposed group (n = 328) that did not receive YHGMS or any other traditional Chinese medicine. Propensity score matching was used to balance baseline characteristics. Primary outcomes included clinical recovery rate and time to recovery. Secondary outcomes included time to normal temperature, symptom resolution rates, and safety profile. Results: After propensity score matching, the YHGMS group demonstrated significantly higher recovery rates on day 3 (52.64% vs Conclusion: YHGMS was associated with faster clinical recovery and symptom resolution in children with AURTI (wind-heat pattern), without significant safety concerns. As monotherapy, YHGMS showed better outcomes than chemical medicine alone; in combination, it also accelerated resolution of clinical symptoms and recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.